Compare ICL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICL | DVA |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 10.1B |
| IPO Year | 2001 | 2002 |
| Metric | ICL | DVA |
|---|---|---|
| Price | $5.36 | $150.71 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $6.10 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.6M | 797.3K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $6.04 | $3.80 |
| Revenue Next Year | $3.27 | $3.04 |
| P/E Ratio | $31.41 | ★ $15.57 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $4.76 | $101.00 |
| 52 Week High | $7.35 | $159.42 |
| Indicator | ICL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 57.20 |
| Support Level | $5.26 | $146.00 |
| Resistance Level | $5.78 | $150.69 |
| Average True Range (ATR) | 0.12 | 4.81 |
| MACD | 0.04 | -1.40 |
| Stochastic Oscillator | 77.27 | 34.35 |
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.